{"name":"Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd.","slug":"hangzhou-zhongmei-huadong-pharmaceutical-co-ltd","ticker":"","exchange":"","domain":"hangzhouzhongmeihuadong.com","description":"","hq":"","founded":0,"employees":"","ceo":"","sector":"Pharma / Biotech","stockPrice":0,"stockChange":0,"stockChangePercent":0,"marketCap":"","metrics":{"revenue":0,"revenueGrowth":0,"grossMargin":0,"rdSpend":0,"netIncome":0,"cash":0,"dividendYield":0,"peRatio":0,"fiscalYear":"FY2026"},"revenueBreakdown":[],"timeline":[{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"}],"diseaseAreas":[{"name":"Other","slug":"other","revenue":0,"percentOfTotal":0,"drugCount":11,"colorKey":"oncology","drugs":[{"name":"HDM1005 3","genericName":"HDM1005 3","slug":"hdm1005-3","indication":"Other","status":"phase_2"},{"name":"HDG1901","genericName":"HDG1901","slug":"hdg1901","indication":"Other","status":"phase_3"},{"name":"HDM1002 200mg, oral, once daily, 52 weeks","genericName":"HDM1002 200mg, oral, once daily, 52 weeks","slug":"hdm1002-200mg-oral-once-daily-52-weeks","indication":"Other","status":"phase_3"},{"name":"HDM1002 400mg, oral, once daily, 52 weeks","genericName":"HDM1002 400mg, oral, once daily, 52 weeks","slug":"hdm1002-400mg-oral-once-daily-52-weeks","indication":"Other","status":"phase_3"},{"name":"HDM1002 placebo, oral, once daily, 52 weeks","genericName":"HDM1002 placebo, oral, once daily, 52 weeks","slug":"hdm1002-placebo-oral-once-daily-52-weeks","indication":"Other","status":"phase_3"},{"name":"HDM1005 1","genericName":"HDM1005 1","slug":"hdm1005-1","indication":"phase_3","status":"phase_3"},{"name":"HDM1005 2","genericName":"HDM1005 2","slug":"hdm1005-2","indication":"Other","status":"phase_3"},{"name":"HDM1702","genericName":"HDM1702","slug":"hdm1702","indication":"Other","status":"phase_3"},{"name":"MC2-01 vehicle","genericName":"MC2-01 vehicle","slug":"mc2-01-vehicle","indication":"Other","status":"phase_3"},{"name":"Wegovy ®","genericName":"Wegovy ®","slug":"wegovy","indication":"Other","status":"marketed"},{"name":"ganagliflozin","genericName":"ganagliflozin","slug":"ganagliflozin","indication":"Other","status":"marketed"}]},{"name":"Oncology","slug":"oncology","revenue":0,"percentOfTotal":0,"drugCount":2,"colorKey":"cardiovascular","drugs":[{"name":"MB-102 DMID","genericName":"MB-102 DMID","slug":"mb-102-dmid","indication":"Relapsed or refractory multiple myeloma","status":"phase_3"},{"name":"MB-102 OMID","genericName":"MB-102 OMID","slug":"mb-102-omid","indication":"Relapsed or refractory multiple myeloma","status":"phase_3"}]},{"name":"Immunology","slug":"immunology","revenue":0,"percentOfTotal":0,"drugCount":1,"colorKey":"immunology","drugs":[{"name":"CAL/BDP Gel","genericName":"CAL/BDP Gel","slug":"cal-bdp-gel","indication":"Plaque psoriasis","status":"phase_3"}]},{"name":"Dermatology","slug":"dermatology","revenue":0,"percentOfTotal":0,"drugCount":1,"colorKey":"neuroscience","drugs":[{"name":"MC2-01 cream","genericName":"MC2-01 cream","slug":"mc2-01-cream","indication":"Inflammatory skin conditions (specific indication not publicly detailed)","status":"phase_3"}]},{"name":"Cardiovascular","slug":"cardiovascular","revenue":0,"percentOfTotal":0,"drugCount":1,"colorKey":"infectious","drugs":[{"name":"Ozempic®","genericName":"Ozempic®","slug":"ozempic","indication":"Type 2 diabetes mellitus","status":"marketed"}]},{"name":"Respiratory","slug":"respiratory","revenue":0,"percentOfTotal":0,"drugCount":1,"colorKey":"respiratory","drugs":[{"name":"Roflumilast Cream 0.3%","genericName":"Roflumilast Cream 0.3%","slug":"roflumilast-cream-0-3","indication":"Chronic obstructive pulmonary disease (COPD)","status":"phase_3"}]}],"pipeline":[{"name":"HDM1005 3","genericName":"HDM1005 3","slug":"hdm1005-3","phase":"phase_2","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"CAL/BDP Gel","genericName":"CAL/BDP Gel","slug":"cal-bdp-gel","phase":"phase_3","mechanism":"CAL/BDP Gel is a topical combination of calcipotriol (vitamin D analogue) and betamethasone dipropionate (corticosteroid) that reduces skin inflammation and normalizes keratinocyte differentiation.","indications":["Plaque psoriasis"],"catalyst":""},{"name":"HDG1901","genericName":"HDG1901","slug":"hdg1901","phase":"phase_3","mechanism":"HDG1901 is an investigational drug in Phase 3 development by Hangzhou Zhongmei Huadong Pharmaceutical, but its specific mechanism of action is not publicly disclosed.","indications":[],"catalyst":""},{"name":"HDM1002 200mg, oral, once daily, 52 weeks","genericName":"HDM1002 200mg, oral, once daily, 52 weeks","slug":"hdm1002-200mg-oral-once-daily-52-weeks","phase":"phase_3","mechanism":"HDM1002 is a small molecule inhibitor that targets a specific molecular pathway involved in metabolic or inflammatory disease.","indications":[],"catalyst":""},{"name":"HDM1002 400mg, oral, once daily, 52 weeks","genericName":"HDM1002 400mg, oral, once daily, 52 weeks","slug":"hdm1002-400mg-oral-once-daily-52-weeks","phase":"phase_3","mechanism":"HDM1002 is a small molecule inhibitor that targets a specific molecular pathway involved in metabolic or inflammatory disease.","indications":[],"catalyst":""},{"name":"HDM1002 placebo, oral, once daily, 52 weeks","genericName":"HDM1002 placebo, oral, once daily, 52 weeks","slug":"hdm1002-placebo-oral-once-daily-52-weeks","phase":"phase_3","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"HDM1005 1","genericName":"HDM1005 1","slug":"hdm1005-1","phase":"phase_3","mechanism":"HDM1005 1 is a small molecule drug.","indications":["phase_3"],"catalyst":""},{"name":"HDM1005 2","genericName":"HDM1005 2","slug":"hdm1005-2","phase":"phase_3","mechanism":"HDM1005 2 is a small molecule drug with an unknown mechanism of action.","indications":[],"catalyst":""},{"name":"HDM1702","genericName":"HDM1702","slug":"hdm1702","phase":"phase_3","mechanism":"HDM1702 is a small molecule inhibitor targeting a specific molecular pathway in development for oncology indications.","indications":[],"catalyst":""},{"name":"MB-102 DMID","genericName":"MB-102 DMID","slug":"mb-102-dmid","phase":"phase_3","mechanism":"MB-102 DMID is a monoclonal antibody targeting CD47.","indications":["Relapsed or refractory multiple myeloma"],"catalyst":""},{"name":"MB-102 OMID","genericName":"MB-102 OMID","slug":"mb-102-omid","phase":"phase_3","mechanism":"MB-102 OMID is a monoclonal antibody targeting CD47.","indications":["Relapsed or refractory multiple myeloma"],"catalyst":""},{"name":"MC2-01 cream","genericName":"MC2-01 cream","slug":"mc2-01-cream","phase":"phase_3","mechanism":"MC2-01 cream is a topical corticosteroid formulation designed to reduce inflammation and provide therapeutic benefit when applied to affected skin areas.","indications":["Inflammatory skin conditions (specific indication not publicly detailed)"],"catalyst":""},{"name":"MC2-01 vehicle","genericName":"MC2-01 vehicle","slug":"mc2-01-vehicle","phase":"phase_3","mechanism":"No mechanism of action is available for MC2-01 vehicle.","indications":[],"catalyst":""},{"name":"Ozempic®","genericName":"Ozempic®","slug":"ozempic","phase":"marketed","mechanism":"Ozempic activates GLP-1 receptors to increase insulin secretion, slow gastric emptying, and reduce appetite, thereby lowering blood glucose levels in type 2 diabetes.","indications":["Type 2 diabetes mellitus","Cardiovascular risk reduction in patients with type 2 diabetes and established cardiovascular disease"],"catalyst":""},{"name":"Roflumilast Cream 0.3%","genericName":"Roflumilast Cream 0.3%","slug":"roflumilast-cream-0-3","phase":"phase_3","mechanism":"Roflumilast is a phosphodiesterase-4 inhibitor, which reduces inflammation by inhibiting the production of pro-inflammatory cytokines.","indications":["Chronic obstructive pulmonary disease (COPD)"],"catalyst":""},{"name":"Wegovy ®","genericName":"Wegovy ®","slug":"wegovy","phase":"marketed","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"ganagliflozin","genericName":"ganagliflozin","slug":"ganagliflozin","phase":"marketed","mechanism":"Small molecule","indications":[],"catalyst":""}],"recentEvents":[],"realNews":[{"url":"https://news.google.com/rss/articles/CBMivAFBVV95cUxQTXlqRnJ2RGRtMTBuR3hXRTk1R2dIU2VvQy1HdjVVMEdEZzIyWE5xd3BxM1JpWUROMW9MTEhnYUdaSGFnSlltNzVScGJzLWVjd3lrZFg2SE02Q1A3dG5kX3ZVYnlYc1hHY1d1LTJ3eE50Uld5UlpQd24wbHNmWDZCUUlLWmZpUlA4bklDV2tva25yc29SUGNIbHV6enp6YjR1Sk52MXdSSHJZMmpUMGhtLU9CWjNreGQ5SGdKeQ?oc=5","date":"2026-03-14","type":"trial","source":"AD HOC NEWS","summary":"Huadong Medicine Advances US Clinical Trial for Injectable HDM2024, Signalling Oncology Expansion - AD HOC NEWS","headline":"Huadong Medicine Advances US Clinical Trial for Injectable HDM2024, Signalling Oncology Expansion","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiwgFBVV95cUxQR2J1NUxFNUhMVUJnZHJ4eEt6SmdVTkN6V3NqRHlWOGhmRHZReTJTVklURm1EUWJubkpNbTliejAzaDdGc25xcktaYlctLUVWbjVzLXFpZHZ2YVFiYms0Y3ViZTcyMjNaWV9LS3BjSHRpMlhqVVBWZTM4b05oSXNpQ2JqU1BRV1Uxa3dtdnJnRU1fbW5XU3Q5VWc3TWZsSWU0T3N6VkpNMjlhNDY3S25UbXVUY0FwSkc1Y1gtZWt0aDZjQQ?oc=5","date":"2026-01-10","type":"pipeline","source":"The Straits Times","summary":"Ozempic for humans, ‘Meowzempic’ for cats? Pharma companies race towards fluffy new frontiers - The Straits Times","headline":"Ozempic for humans, ‘Meowzempic’ for cats? Pharma companies race towards fluffy new frontiers","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMimwFBVV95cUxQOVdDamNUWE40U294N3poX3prS2F2cjVkTU1STEJnMks0UTZuSk9ZczF4bld0ZWhoYUdlWDdRNGxhUGZSd3M0T3R6X1otNjN5X0lJZXZUbmppSDBsRHVzQTROTjcxY2lQNFhJR19LVlVxYnhKd0ctY1BGYmM2VGtVcWx1M0NvTjdjemxIbnVLZlZSbnZCV0oxVXVINA?oc=5","date":"2025-10-29","type":"deal","source":"BioWorld News","summary":"Qyuns and Roche partner in $1B+ bispecific antibody deal - BioWorld News","headline":"Qyuns and Roche partner in $1B+ bispecific antibody deal","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiowFBVV95cUxNODVjTUhXRXY4VkdTdEVlQWtsTUp6aTRwTkwwNkpDNnB5ZWdza1VyUzh6b21CWDIyQ0FRU1JfNllhdHR4YU4tNXk1SkpXaGRkdVZncE1rZnNFellIWk1SU3llUW9RNXVFdjkyLVkxSldWblVVMm54d0FwVmRiSDhjTzg0cEF1aGt6ZjlLb2hEQnRnYkxzOGpYNVNMQTd3TXg5V2pR?oc=5","date":"2025-02-20","type":"deal","source":"BioWorld News","summary":"Radiance wins ROR1 ADC rights from CSPC in potential $1B+ deal - BioWorld News","headline":"Radiance wins ROR1 ADC rights from CSPC in potential $1B+ deal","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMimwFBVV95cUxNQXVVQW1fOGZVUWEtYUxMUFFXVUtqRnptaV95dnFsOVplLXV2M3RUNk5rcnFieU5GZE9kemh6dk03Tl84QV80WjdvblZENnRuU3NYTVd2NE51LXJ5NzF0YnY0VkMtWGlHRXJvNGZVYWFOUkVOVmpYZHIzamdPdU9JUDdFeEtpX3A1Vktla01hNkZmS09MWVBWM1l4OA?oc=5","date":"2024-09-17","type":"pipeline","source":"BioWorld News","summary":"Big pharma eyes China ‘at forefront of GLP-1 revolution’ - BioWorld News","headline":"Big pharma eyes China ‘at forefront of GLP-1 revolution’","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMinAFBVV95cUxPdW5GOU45aE10NlNVcGl6X2NrS3psclFMaVNJR24zRXlEdHNvdE9HSFR4V3hRTGFZemFBNTBSbF9Ybm1PcnlrODhVcWQxUzU1R0tpQUF0cGZfakJ1ckNpeFJLUm9lNURMSlluYmJTeVRmNUpvRVladm16MGpfbm9tdkpEenQ1Tm9lQl9iSUNINTV1aWpDdGw0cVdfcWo?oc=5","date":"2024-08-22","type":"pipeline","source":"European Pharmaceutical Review","summary":"Harnessing the GLP-1R medicine wave - European Pharmaceutical Review","headline":"Harnessing the GLP-1R medicine wave","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMixwFBVV95cUxOWnN2YklUTjhWTkVZYVV2LUJxYV9LcTlwbWhtWjJRUWhyWGlxdnREQXFldmkxUFdOY0ctcV90Y0tjQk92YS02YUd1TS1taEJxOVRTbnBxa3BpYWFOWGpIZ3pUMlNObmtyRV9wR3ZBZWIyNVlwQWhuY2tILXBwRVJzSlR3NzRYQjM2UHVlaEtpX05CZWY5QUhTdnNISWc4c1Fua3h1ZzVQQ1pCTFViWlZESWc2NlVWT01XQmE4RkVJZjZBSzd1OTBj?oc=5","date":"2024-07-17","type":"trial","source":"BioPharma APAC","summary":"Sanyou Bio and Huadong Medicine Advance SYHD001 ADC Drug to Phase I Clinical Trials - BioPharma APAC","headline":"Sanyou Bio and Huadong Medicine Advance SYHD001 ADC Drug to Phase I Clinical Trials","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMi9gFBVV95cUxOV2J3TzhLRFZabkdzcDNxNktyR0hWOTY1S2ZHTjNLSjlMTFl2RXlwRnFEZWFmNk9XaGxNOWtHZE96Q3JVbUpaMnhqek9rcGQ0UEV5QzNfZnB0alJzRjhqWEVrdlBnalE0M0tGeEV3SjQ3YUQyWFpVZGFvbmk2Ylpfc1hOTXNULWRmbWhJVDJwamppZ2RjSTVXWGpDUWc1ZUJFRUNObVI5RjVoRkpKM3Z0NDJsVW44UGUxWEdzTzFtQWpzMnY1dUtCVW02TFhfdElSMTNud1VWM1htVEVaVnpTSGpqWHBkTlR6RUhNQlpzbWZCV25PX0E?oc=5","date":"2024-06-27","type":"trial","source":"BioPharma APAC","summary":"Huadong Medicine Announces Positive Phase I Clinical Trial Results for Oral GLP-1 Receptor Agonist HDM1002 in China - BioPharma APAC","headline":"Huadong Medicine Announces Positive Phase I Clinical Trial Results for Oral GLP-1 Receptor Agonist HDM1002 in China","sentiment":"positive"}],"patents":[],"drugCount":17,"phaseCounts":{"phase_2":1,"phase_3":13,"marketed":3},"enrichmentLevel":0,"visitCount":5,"keyCompetitors":[],"therapeuticFocus":[],"financials":null,"yahoo":null}